Novartis has announced that the Phase IIIb MAXIMISE clinical trial of its Cosentyx...
ReveraGen’s vamorolone improves muscle function in DMD trial
ReveraGen BioPharma has reported positive results from the ongoing VBP15-LTE clinical trial where vamorolone improved muscle function after 18 months of therapy in Duchenne muscular dystrophy (DMD) patients.
Ipsen reports positive data for Dysport to treat limb spasticity
Ipsen has reported positive data from the ENGAGE clinical trial of Dysport (abobotulinumtoxinA) in adults with upper and lower limb spastic hemiparesis.
Filgotinib shows improvements in rheumatoid arthritis trial
A Phase III clinical trial led by a Stanford University School of Medicine investigator has demonstrated that Gilead Sciences’ filgotinib led to substantial improvements in rheumatoid arthritis patients who did not respond to existing therapies.
Sandoz starts enrolment in biosimilar denosumab trial
Novartis subsidiary Sandoz has commenced patient enrolment in the Phase I/III ROSALIA clinical trial of its proposed biosimilar denosumab to treat osteoporosis.
Mallinckrodt ends Acthar Gel’s Phase IIb trial in ALS
Mallinckrodt has permanently suspended a Phase IIb clinical trial of its Acthar Gel (repository corticotropin injection) in patients with amyotrophic lateral sclerosis (ALS).
Novartis’ Cosentyx shows efficacy in psoriatic arthritis trial
Novartis has announced that the Phase IIIb MAXIMISE clinical trial of its Cosentyx (secukinumab) drug met primary and key secondary endpoints in patients with psoriatic arthritis (PsA).
Pfizer reports favourable outcomes for rheumatoid arthritis drug
Pfizer has reported positive findings from the 12-month Phase IIIb/IV ORAL Shift clinical trial of Xeljanz (tofacitinib), a JAK inhibitor, to treat moderately to severely active rheumatoid arthritis (RA) in adults.
Paradigm reports positive RWE data for knee osteoarthritis therapeutic
Paradigm Biopharmaceuticals has reported positive real-world evidence (RWE) of its injectable pentosan polysulfate (iPPS), an antithrombotic agent, in 205 patients suffering from knee osteoarthritis (OA).
Lilly’s Taltz improves spondyloarthritis symptoms in Phase III trial
Eli Lilly has reported positive results from the Phase III COAST-X clinical trial of Taltz (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA).